Press Releases

Foster City, CA and Louisville, CO – October 24, 2011 – Gilead Sciences, Inc. (Nasdaq: GILD) and GlobeImmune, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of … Continue reading →

LOUISVILLE, Colo., Aug. 31, 2011 – GlobeImmune Inc. announced today the promotion of Jeffrey Dekker to Vice President of Finance. Mr. Dekker previously served as Controller and Senior Director Finance at GlobeImmune since joining the company in 2006. Before joining … Continue reading →

Oncology data to be presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO)

Continue reading →

LOUISVILLE, Colo., November 3, 2010 – GlobeImmune Inc. today announced that the company has been awarded three grants totaling $733,438 under the federal Therapeutic Discovery Project Program. GlobeImmune will receive grant money for each of the following clinical-stage therapeutic vaccine … Continue reading →

Additional data suggest that cellular immunity may be a fundamental deficit in hardest-to-treat IL28B T/T genotype patients and is corrected by GI-5005 Data to be presented at annual meeting of the American Association for the Study of the Liver Disease … Continue reading →

LOUISVILLE, Colo., October 28, 2010 – GlobeImmune Inc. today announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus (HCV) infection. The Company previously reported data demonstrating a … Continue reading →

Immunology data also to be presented in poster session LOUISVILLE, Colo., October 1, 2010 – GlobeImmune Inc. today announced that an abstract related to GI-5005, its Phase 2 investigational hepatitis C virus (HCV) product candidate, has been accepted for a … Continue reading →

Data Showing Correlation of GI-5005 Therapeutic Vaccine Treatment Response and IL-28 B Genotype Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 19, 2010 – GlobeImmune Inc. announced Phase 2b data … Continue reading →

Final Phase 2b Data for GI-5005 in Treatment-naïve Patients Presented at 45th Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., April 15, 2010 – GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, … Continue reading →

Sustained Virologic Response, Pharmacogenomic and Biopsy Analysis of HCV Patients Receiving GI-5005 Therapeutic Vaccine to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo., March 17, 2010 – GlobeImmune Inc. today … Continue reading →

LOUISVILLE, CO, January 19, 2010 – GlobeImmune Inc., a company developing novel therapies for patients with cancer and infectious diseases, today announced a Series E Preferred Stock financing of $17.5 million. The round was led by new investors Generali Financial … Continue reading →

Phase 2b Data Presented at American Association for the Study of Liver Diseases Meeting LOUISVILLE, Colo., Nov. 2, 2009 – GlobeImmune Inc. will present Phase 2b data today at the 60th Annual Meeting of the American Association for the Study … Continue reading →

LOUISVILLE, Colo., Oct. 6, 2009 – GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association … Continue reading →

Tarmogen® Technology Platform Creates Powerful, Targeted Immune Response to Diseased Cells and Drives Family of Oncology-Focused Products LOUISVILLE, Colo. & SUMMIT, N.J. – May 15, 2009 – GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration … Continue reading →

Twelve Week Data to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo. – April 23, 2009 – Twelve-week Phase 2 clinical trial data show that patients treated with GI-5005, GlobeImmune’s … Continue reading →

LOUISVILLE, Colo., April 16, 2009 – GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in patients with metastatic cancers that over-express carcinoembryonic antigen (CEA).  This … Continue reading →

Four-Week Data Comparing GI-5005 Plus Standard of Care vs. Standard of Care to be Presented Next Week in Late-Breaking Poster at AASLD Meeting AASLD President Will Highlight Data at President’s Press Conference LOUISVILLE, Colo., Nov. 1, 2008 – Four-week Phase … Continue reading →

Data to be Presented Next Week in Late-Breaking Poster at AASLD Annual Meeting LOUISVILLE, Colo., Oct. 28, 2008 – GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company’s therapeutic vaccine candidate … Continue reading →

LOUISVILLE, Colo., Sept. 24, 2008 – GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 59th Annual Meeting of the American Association … Continue reading →

LOUISVILLE, CO, July 9, 2008 – GlobeImmune, Inc. announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to jointly develop products intended to treat … Continue reading →

LOUISVILLE, CO – June 24, 2008 – FierceBiotech and GlobeImmune, Inc. announced today that GlobeImmune has been named to the annual FierceBiotech “Fierce 15″ list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech … Continue reading →

LOUISVILLE, CO, May 20, 2008 – GlobeImmune, Inc. announced today completion of the planned enrollment of 120 subjects in a Phase 2 clinical trial to evaluate the GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 … Continue reading →

LOUISVILLE, CO, March 25, 2008 – GlobeImmune, Inc. announced today the addition of J. William Freytag, Ph.D. to its Board of Directors. “Dr. Freytag brings over 25 years of research, product development and commercialization experience to the Board,” said Timothy … Continue reading →

FOR IMMEDIATE RELEASE GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer at Memorial Sloan Kettering LOUISVILLE, CO, March 19, 2008 – GlobeImmune, Inc. announced today the initiation of a Phase … Continue reading →

FOR IMMEDIATE RELEASE: LOUISVILLE, CO – January 3, 2007 – GlobeImmune, Inc. announced today that President and Chief Executive Officer Timothy C. Rodell, M.D. will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco … Continue reading →

LOUISVILLE, CO, December 19, 2007 – GlobeImmune, Inc. announced today the initiation of the Company’s Phase 2 clinical trial to evaluate GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 is being evaluated as a potential … Continue reading →

LOUISVILLE, CO, November 6, 2007 – GlobeImmune, Inc. today announced results from the additional higher dose cohorts from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating the safety, immunogenicity and initial efficacy of GI-5005 in patients with chronic hepatitis … Continue reading →

LOUISVILLE, CO, November 1, 2007 – GlobeImmune, Inc. today announced that additional high dose results from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating GI-5005 as a treatment of chronic hepatitis C infection will be the subject of a … Continue reading →

LOUISVILLE, CO, October 25, 2007 – GlobeImmune, Inc. announced today results from research on its GI-10001 Tarmogen®, which is being investigated for the treatment of  drug resistant  chronic myelogenous leukemia (CML).  Leukemia driven by the Bcr-Abl T315I mutation, known as … Continue reading →

LOUISVILLE, CO, September 26, 2007  GlobeImmune Inc. today announced it has raised $41.2 million through a Series C Preferred Stock financing.  This round was led by Wexford Capital LLC, and as a result of its investment, Paul A. Mieyal, Ph.D. … Continue reading →

LOUISVILLE, CO, January 5, 2007, GlobeImmune, Inc. announced today that President and Chief Executive Officer Timothy C. Rodell, M.D. will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 10, 2007 … Continue reading →

LOUISVILLE, CO, October 30, 2006, GlobeImmune, Inc. today announced positive interim results from Study GI-5005-01, a randomized, placebo-controlled, multi-center, dose-escalation, Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus (HCV). The data were presented today at … Continue reading →

LOUISVILLE, CO, October 17, 2006, GlobeImmune, Inc., announced today that the interim results from a placebo-controlled Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus will be presented at the 57th Annual Meeting of the American … Continue reading →

LOUISVILLE, CO, August 28, 2006, GlobeImmune, Inc., today announced that John Frenz Ph.D. has joined the company as Vice President of Operations.  Dr. Frenz is responsible for managing all manufacturing operations and process development for GlobeImmune. Dr. Frenz comes to … Continue reading →

LOUISVILLE, CO, August 9, 2006, GlobeImmune, Inc., today announced the appointment of Jules Harris M.D. to the GlobeImmune scientific advisory board.  Dr. Harris joins existing advisors Teresa Brentnall M.D., Paul Bunn M.D., Dr. Francis Chisari M.D., Charles Dinarello M.D., Edgar … Continue reading →

Louisville, CO, June 7, 2006, GlobeImmune, Inc. today announced the initiation of a randomized, placebo-controlled, multi-center Phase 2 clinical trial of GI-4000, GlobeImmune’s therapeutic vaccine for the treatment of patients with early-stage pancreas cancer.  The primary goal of the study … Continue reading →

Louisville, CO, May 22, 2006 – GlobeImmune today announced that it has been named a winner of the prestigious Red Herring 100 award.  GlobeImmune was recognized for its pioneering work on yeast-based products called Tarmogens (Targeted Molecular Immunogens), which activate … Continue reading →

GlobeImmune Adds to Executive Management Team LOUISVILLE, CO May 15, 2006GlobeImmune, Inc., today announced that Jeffrey Rona has joined as Chief Business Officer. “Jeff’s extensive experience will add significantly to the senior management team and help us continue to grow … Continue reading →

LOUISVILLE, CO, January 10, 2006, GlobeImmune, Inc., today announced the final closing of a Series B Preferred Stock financing. GlobeImmune added an additional $4.1 million to the previously announced first close of $34.3 million, bringing the total amount raised in … Continue reading →

LOUISVILLE, CO, December 13, 2005, GlobeImmune, Inc. today announced the relocation of its corporate headquarters to Louisville, Colorado. The new GlobeImmune address is: 1450 Infinite Drive Louisville CO, 80027 The telephone number is: 303-625-2700 The main fax number is: 303-625-2710 … Continue reading →

DENVER, CO, September 14, 2005, GlobeImmune, Inc., a biopharmaceutical company developing immunotherapy products called Tarmogens™ for the treatment of cancer and chronic infectious diseases, today announced the initial successful closings of a Series B Preferred Stock financing, raising $34.3 million.  … Continue reading →

DENVER, CO, August 31, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Carl H. June, M.D. to its Scientific Advisory Board. “We … Continue reading →

DENVER, CO, August 3, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Francis V. Chisari, M.D. to its Scientific Advisory Board. “We … Continue reading →

DENVER, CO, July 26, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers, develops and manufactures immunotherapeutic products known as Tarmogens™ to treat cancer and infectious disease, today announced that it has initiated a Phase 1b study of GI-5005, a Tarmogen … Continue reading →

DENVER, CO, January 17, 2005 – GlobeImmune and Mycologics announce today that they have signed a non-exclusive research license and option agreement under which Mycologics will pursue select antifungal products under the GlobeImmune Tarmogen Technology. The license agreement enables MycoLogics … Continue reading →

Aurora, CO, January 5, 2005  GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of two management team members. “We are pleased that GlobeImmune has been able to fill these two key positions,” said Timothy C. Rodell, M.D., GlobeImmune’s … Continue reading →

Aurora, CO, September 13, 2004. GlobeImmune, Inc. today announced the appointment of Dr. Paul Bunn to its Scientific Advisory Board. Dr. Bunn is the Grohne-Stapp Endowed Professor of Oncology Research and Director of the University of Colorado Cancer Center in … Continue reading →

Aurora, CO, August 26, 2004. GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of five management team members including key hires at the director and department head level. “We are pleased that GlobeImmune has continued to attract the … Continue reading →

AURORA, CO, May 25, 2004 – GlobeImmune, Inc. today announced that the Company’s Investigational New Drug (IND) application for the GI-4000 product series, filed with the U.S. Food & Drug Administration last month, has become effective after the initial 30-day … Continue reading →

AURORA, CO, May 13, 2004 – GlobeImmune, Inc. today announced that Teresa Brentnall, MD, Edgar Engleman, MD, Edward Mocarski, PhD, Alan Venook, MD, and Bruce Walker, MD have been appointed to the company’s Scientific Advisory Board. “These outstanding professionals in … Continue reading →

AURORA, Colorado, December 19, 2003 — GlobeImmune, Inc. today announced that Dr. Alex Franzusoff has been appointed Vice President of Research. Dr. Franzusoff, one of the Company’s three scientific founders, was most recently Associate Professor of Cellular and Developmental Biology … Continue reading →

AURORA, Colo., June 18, 2003 — GlobeImmune, Inc. today announced the closing of a Series A Preferred venture financing round. The round provides for up to a total of $8 million in two tranches, with closure of the second tranche … Continue reading →